MAPT and Alzheimer disease: The present study confirms previous investigations that the changes of CSF tau and Aβ42 is very modest over time in individual patients with AD[8], [9], [10], [11], [12], [13], [14], which might indicate that these CSF biomarkers may serve as sensitive tools to identify and monitor even minor biochemical changes induced by treatments that are directed against these targets, such as Aβ immunotherapy.